Advertisement
Advertisement
TOPIC

Biomedicine: Industry Trends

Related Topics:
Biomedicine: Industry Trends
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
Clara Chan, CEO of Hong Kong Investment Corporation, speaks at the Global Health Summit at the Hong Kong Convention and Exhibition Centre on August 7. Photo: Jonathan Wong
Hong Kong economy

Editorial | Hong Kong is stepping up its contribution to global healthcare

The Global Health Summit highlighted the city’s potential to become an elite international hub for biomedicine and biotechnology.

Stanford University

Patience needed before human gene therapy trials, Stanford expert says

videocam
China technology

The next tech race? China launches push to leapfrog US in ‘brain chip’ devices

14
China’s private sector

China’s drug firms set to compete on the world stage, analysts say

Amid systemic efficiency and a wave of innovation, the country’s biotech sector is expanding at a pace that has caught the market off guard.

4
With an efficiency edge that transcends simple cost advantages, China is set to see the emergence of a home-grown drug giant capable of competing with global players. Photo: Shutterstock
China technology

China races to develop brain-computer interfaces that can be inserted in minutes

The technology – which allows patients to control digital devices using their thoughts – can be implanted like a stent in just a few minutes.

China’s private sector

Global pharma giants turn to Chinese biotech to tap innovation, valuation growth

The foreign investments can help Chinese companies grow and compete on the global stage, according to Citic Securities.

Advertisement
Advertisement
Advertisement
China’s private sector

Sugar for the pill: US$8b fund boosts Hong Kong’s biotech hub ambitions

Hong Kong Investment Corporation is stepping up its efforts to position itself amid Beijing’s challenge to US pharmaceutical dominance.

Clara Chan Ka-chai, CEO of Hong Kong Investment Corporation (HKIC) Photo: Enoch Yiu
Science

China biotech sector fears policy backlash after girl dies in gene-editing trial

Scientist says child’s death reveals ‘serious failures in risk assessment, transparency and institutional oversight’.

videocam
US-China trade war

Record Chinese biotech out-licensing meets rising US scrutiny

Surging cross-border deals out of China are running headlong into intensifying US national security fears.

videocam
22
Banking & finance

As weight-loss drug orders surge, global funds pile into China’s WuXi AppTec

Pharmaceutical contractor’s GLP-1 programmes and surging stock gains have made it a magnet for global investors.

WuXi AppTec was expected to release its half-year earnings results on August 3. Photo: Handout
China’s private sector

‘Historic breakthrough’: China approves novel drug ahead of US, Japan and Europe

Push to accelerate novel drug reviews promises earlier access to breakthrough therapies for patients long left waiting.

China is pushing to accelerate novel drug reviews. Photo: Shutterstock
Banking & finance

Healthcare IPO wave: US biotech firm picks Hong Kong over Nasdaq for listing

Axiom Biosciences founder says Hong Kong investors show greater maturity than Nasdaq in handling biotech companies.

China’s private sector

‘Systemic leap’: China’s drug innovation push yields bumper crop

Home-grown therapies account for 80 per cent of approvals in first six months of the year.

videocam
United States

Lab monkey prices soar as China’s biotech boom fuels windfall for breeders

In the first six months to June 30, there were 81 cross-border deals for innovative medicines worth a combined record of US$110 billion.

China accounts for about 30 per cent of all new medicines currently under development worldwide, ranking second globally. Photo: Shutterstock Images
Banking & finance

Mainland funds boost stakes in Hong Kong-listed biotech amid value dislocation

Analysts say valuation of the sector is attractive, with biotech firms trading relatively cheaply.

Hong Kong’s skyline is seen from The Peak on June 1. Photo: Karma Lo
China manufacturing

The next rare earths? Why US fears another Chinese manufacturing advantage

China’s production of drug inputs has boomed in recent years, increasing market share and prompting fears of weaponisation in Washington.

videocam
26
China’s private sector

Europe beckons: can Chinese medical device makers thrive amid trade barriers?

Chinese medical device companies eye Europe for relief from hospital probes at home while navigating protectionism overseas.

Advertisement
Advertisement
Advertisement
China’s private sector

Can AI collaborations power China’s next wave of blockbuster drug deals?

China develops 30 per cent of new therapies worldwide as it rises to the top tier in innovation efficiency, drug supervision official says.

A pharmaceutical manufacturing line. Photo: Shutterstock
Hong Kong economy

Opinion | Hong Kong can be the Asia-Pacific’s longevity hub

City has unique conditions to be the premier regional hub for longevity research, clinical trials, regulatory approval and capital scaling.

videocam
Science

Meet Biomni: the free powerful biomed AI agent turning data into hypotheses

Stanford team that includes two Chinese among its main developers says system can turn a plain-language request into an entire research workflow.

videocam
China’s private sector

China’s biotech boom: RAS-targeted drugs challenge US dominance

The rapid development of China’s RAS-targeted cancer drugs could reshape global oncology and unlock the country’s undervalued biotech firms.

Chinese biotech and innovative drug firms are rapidly closing the gap with its US rivals as it continues to develop RAS-targeted cancer therapies. Photo: Shutterstock
China’s private sector

China AI drug-design deals swell as US scrutiny mounts

Global pharmaceutical firms are tapping into Chinese artificial intelligence assets before patents expire on blockbuster drugs, advancing AI-driven biotech.

videocam
Industry insiders say AI-powered drug-design tools have the potential to shorten development timelines from years to as few as 18 months. Photo: Shutterstock
China’s private sector

Hong Kong draws royalties giant as mainland China biotech licensing heats up

Royalty financing offers new cash source as global investors pursue Chinese drug breakthroughs despite US pressure, Royalty Pharma says.

China’s private sector

China’s first AI-powered cancer vaccine production line set to launch in Beijing

Likang Life Sciences says it has developed a personalised vaccine using advanced tech to identify tumour-specific mutations.

China’s private sector

China is fretting over a demographic crisis – but what companies might benefit?

Goldman Sachs says pharmaceutical, biotech sectors could see strongest tailwinds, while car industry, tech hardware makers may struggle.

Two elderly people in Beijing on June 1. Photo: EPA
China’s private sector

China’s biotech boom: record 5,215 clinical drug trials reported in 2025

Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in Washington.

Cancer research being conducted in a modern lab. Cancer treatments remained the top focus of the record 5,215 clinical drug trials in China last year. Photo: Shutterstock
Medicine

China closing in but US leads in biotech quality and commercial reach: survey

The Cure survey said China leads ⁠in clinical development and supply chain, and rated US funding cuts a bigger threat than China competition.

videocam
China’s private sector

Bigger, fewer, tougher: the new era of China-US biotech partnerships

China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement